Action 6622 ZHAOKE OPHTHALMOLOGY LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Zhaoke Ophthalmology Limited

Actions

6622

KYG989M51017

Marché Fermé - Hong Kong S.E.
Autres places de cotation
 10:08:20 26/04/2024 		Varia. 5j. Varia. 1 janv.
1,51 HKD -1,95 % Graphique intraday de Zhaoke Ophthalmology Limited -2,58 % -61,77 %
08/04 Zhaoke Ophthalmology Limited annonce la démission de Chen Yu Has en tant que directeur non exécutif CI
27/03 Zhaoke Ophthalmology Limited publie ses résultats pour l'exercice clos le 31 décembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Zhaoke Ophthalmology Limited Announces the Resignation of Chen Yu Has as Non-Executive Director
Zhaoke Ophthalmology Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Distribute Eye Drop in Korea
Zhaoke Ophthalmology's Investigational New Drug Applications for Pupil-Modulating Eye Drops Given Green Light by Chinese Regulator
Zhaoke Ophthalmology Limited Announces Investigational New Drug Applications for Clinical Trial of Brimachol PF for the Treatment of Presbyopia
Zhaoke Ophthalmology Limited Announces Executive Changes
Lee’s Pharmaceutical Sells Rights for Eyprotor to Zhaoke Ophthalmology for 60 Million Yuan
Zhaoke Ophthalmology's Myopia Treatment Shows Strong Safety, Efficacy in Phase 3 Study
Zhaoke Ophthalmology Limited Announces Positive Top-Line Results from NVK002 One-Year Phase III Clinical Trial (Mini-Champ) in China for the Treatment of Myopia Progress in Children and Adoption in China
Zhaoke Ophthalmology Enlists Patients for 2 Drug Trials; Will Refile NDA for Eye Gel
Zhaoke Ophthalmology Limited Provides Updates on Phase III Clinical Trials for Tab014 and Epinastine Hcl and Update on the New Drug Application for Cyclosporine A Ophthalmic Gel
Zhaoke Ophthalmology's Loss Widens in H1
Zhaoke Ophthalmology Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Zhaoke Ophthalmology Concludes Phase III Trial of Myopia Medication
Zhaoke Ophthalmology Limited Announces Completion of NVK002 Phase III Bridging Clinical Trial
Zhaoke Ophthalmology Enters into Exclusive License, Supply and Distribution Agreement with Eyedetec Medical to Commercialize Eye Lipid Mobilizer for the Treatment of Dry Eye Disease
US FDA Approves New Drug Application of Zhaoke Ophthalmology's Eye Drops for Nearsightedness; Shares Surge 12%
Zhaoke Ophthalmology Partner Achieves Positive Top-Line Results from Eye Drop's Phase 3 Trial
Zhaoke Ophthalmology Loss Narrows in 2022
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Commercialize Myopia Drug in South Korea
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 6622
  4. Actualités Zhaoke Ophthalmology Limited
  5. Autres langues